We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inhibiting the Growth of Pancreatic Adenocarcinoma <i>In Vitro</i> and <i>In Vivo</i> through Targeted Treatment with Designer Gold Nanotherapeutics.
- Authors
Kudgus, Rachel A.; Szabolcs, Annamaria; Khan, Jameel Ahmad; Walden, Chad A.; Reid, Joel M.; Robertson, J. David; Bhattacharya, Resham; Mukherjee, Priyabrata
- Abstract
Background: Pancreatic cancer is one of the deadliest of all human malignancies with limited options for therapy. Here, we report the development of an optimized targeted drug delivery system to inhibit advanced stage pancreatic tumor growth in an orthotopic mouse model. Method/Principal Findings: Targeting specificity in vitro was confirmed by preincubation of the pancreatic cancer cells with C225 as well as Nitrobenzylthioinosine (NBMPR - nucleoside transporter (NT) inhibitor). Upon nanoconjugation functional activity of gemcitabine was retained as tested using a thymidine incorporation assay. Significant stability of the nanoconjugates was maintained, with only 12% release of gemcitabine over a 24-hour period in mouse plasma. Finally, an in vivo study demonstrated the inhibition of tumor growth through targeted delivery of a low dose of gemcitabine in an orthotopic model of pancreatic cancer, mimicking an advanced stage of the disease. Conclusion: We demonstrated in this study that the gold nanoparticle-based therapeutic containing gemcitabine inhibited tumor growth in an advanced stage of the disease in an orthotopic model of pancreatic cancer. Future work would focus on understanding the pharmacokinetics and combining active targeting with passive targeting to further improve the therapeutic efficacy and increase survival.
- Subjects
ADENOCARCINOMA; IN vitro studies; DRUG delivery systems; PANCREATIC cancer; NITROBENZYLTHIOINOSINE; PHARMACOKINETICS
- Publication
PLoS ONE, 2013, Vol 8, Issue 3, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0057522